Skip to main content
. 2009 Sep 24;5:757–766. doi: 10.2147/tcrm.s5189

Figure 4.

Figure 4

Tolerability of lacosamide (LCM) in patients with epilepsy. Incidence of treatment-emerging events in patients receiving placebo, LCM 200 mg/day and LCM 400 mg/day during phase III studies for treatment of partial epilepsy (safety sets of studies SP667, SP754, and SP755).